QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text (PDF) All Versions of this Article: jpet.102.048280v1 305/3/864    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lanz, T. A. Articles by Merchant, K. M. Search for Related Content PubMed PubMed Citation Articles by Lanz, T. A. Articles by Merchant, K. M.

NEUROPHARMACOLOGY

The -Secretase Inhibitor N-[N-(3,5-Difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl Ester Reduces A Levels in Vivo in Plasma and Cerebrospinal Fluid in Young (Plaque-Free) and Aged (Plaque-Bearing) Tg2576 Mice

Department of Neurobiology, Pharmacia Corporation, Kalamazoo, Michigan

Received December 17, 2002; accepted February 21, 2003.

	Abstract

Top Abstract Materials and Methods Results Discussion References

 
Acute, s.c. administration of a -secretase inhibitor, N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester (DAPT), to young PDAPP mice dose dependently decreases cortical amyloid- (A). The present studies replicated these findings in Tg2576 mice and examined further whether DAPT would reduce cerebrospinal fluid (CSF) A comparably in young (plaque-free) and aged (plaque-bearing) mice. In the first study, vehicle or DAPT (10, 30, or 100 mg/kg s.c.) administered to young Tg2576 mice (6 months old) dose dependently reduced A peptide levels in the cortex as seen previously in the PDAPP mice. Additionally, a dose-dependent decrease in plasma A levels was evident. The same dosing regime was applied next to aged mice (17 months old) to assess A changes in the CSF in addition to plasma and brains. DAPT dose dependently reduced A levels in the CSF and plasma, but not in the brain wherein A levels were 400 to 500 times higher than those in young mice, consistent with a large pool of A extracted from amyloid deposits. In subsequent studies, effects of oral DAPT (100 or 200 mg/kg) were examined concurrently in young and aged mice. DAPT reduced A levels in CSF and plasma to a similar extent at both ages. In contrast, DAPT reduced brain A levels primarily in young mice, with minimal effects in aged mice. These results demonstrate that A levels in CSF and plasma decrease dose dependently after -secretase inhibition, and this response is not affected by amyloid plaque burden. We conclude that CSF and plasma A may offer a clinically applicable, mechanism-based biomarker for inhibitors of A production.

The focus on A as a key pathological component of AD has led to examination of - and -secretases as possible targets for therapeutic intervention. The inhibition of either - or -secretase in vitro decreases the production of A (Rishton et al., 2000; Shearman et al., 2000; Dovey et al., 2001; Steinhilb et al., 2001). The availability of transgenic mice simulating clinical brain amyloidosis has enabled in vivo, preclinical proof-of-concept studies to investigate the utility of - or -secretase inhibitors for potential disease-modifying treatment of AD. Using young PDAPP mice expressing human APP with the "Indiana" mutation (V717F), Dovey et al. (2001) demonstrated dose-dependent decreases in cortical A levels after acute administration of the -secretase inhibitor N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester (DAPT). In addition, chronic administration of DAPT to young PDAPP mice significantly prevents age-dependent amyloid plaque deposition in the brain (May et al., 2001). These data strengthen the rationale to test the efficacy of -secretase inhibitors in treatment of AD.

To facilitate clinical studies of -secretase inhibitors, it is critical to have a pharmacodynamic biomarker that can provide evidence of pharmacological activity of the agent being tested. Because A peptides are secreted in the extracellular fluid, including the cerebrospinal fluid (CSF) and plasma of AD patients as part of the constitutive APP metabolism (Ida et al., 1996; Seubert et al., 1992), we set out to test the hypothesis that A levels in these clinically accessible fluids may provide a biomarker of -secretase inhibition. To this end, we had two specific aims. First, to replicate the observations of Dovey et al. (2001) on DAPT effects on cortical A levels in young Tg2576 mice expressing human APP with the "Swedish" mutation (Hsiao et al., 1996). Second, we examined whether the -secretase inhibitor would reduce CSF and plasma A levels in the Tg2576 mouse, independent of the status of amyloid plaque load in the brain. The latter study was critical because several reports suggest profound alterations in CSF A and moderate changes in plasma A levels in AD patients that indicate altered A kinetics among the three interrelated compartments: the brain, CSF and plasma. Specifically, A(1-42) levels in the CSF of AD patients are reduced by about 50% compared with age-matched controls (Motter et al., 1995; Nitsch et al., 1995; Andreasen et al., 1999; Mehta et al., 2000), although a few studies have not replicated these findings (for review, see Andreasen and Blennow, 2002). There have been two reports of an increase in A levels in the plasma of AD patients (Matsubara et al., 1999; Mayeux et al., 1999), but several others show no change (Ida et al., 1996; Scheuner et al., 1996; Tamaoka et al., 1996; Mehta et al., 2000). Although not fully understood, one factor putatively contributing to the alteration in A kinetics is thought to be the progressive accumulation of amyloid plaques in the brain. Indeed, both CSF and plasma A levels are reduced age dependently in Tg2576 mice such that an inverse relationship exists between brain amyloid plaque deposition and CSF or plasma A levels (Kawarabayashi et al., 2001). Hence, we considered it critical to evaluate modulation of A dynamics in the CSF, brain, and plasma by amyloid plaque load after -secretase treatment. Our data demonstrate that -secretase inhibition lowers A levels in both the CSF and plasma in the APP transgenic mouse and that amyloid plaque burden does not affect this response. The significance of these data is discussed.

	Materials and Methods

Top Abstract Materials and Methods Results Discussion References

 
Animals and in Vivo Drug Administration. Six- and 17-month old female transgenic mice overexpressing the human APP gene with the Swedish double mutation (K670N/M671L) under the transcriptional control of the hamster prion protein promoter (Tg2576 line; Hsiao et al., 1996) were used for the studies. In the first study, young and aged mice were dosed s.c. with vehicle (5% ethanol in corn oil) or DAPT solution at the final volume of 10 ml/kg. The doses of DAPT (10, 30, 100 mg/kg s.c.) and vehicle were selected to replicate the study by Dovey et al. (2001). In the second experiment, young and aged mice were given 100 or 200 mg/kg DAPT p.o., in the same vehicle. The route of administration was changed due to difficulty in dissolving the higher dose (200 mg/kg) of DAPT in the vehicle and to minimize the potential for drug precipitation after s.c. administration. For the oral study, DAPT was administered as a suspension at 10 ml/kg after an overnight fast. Each treatment group was composed of 15 mice at each age.

Tissue Isolation and Processing. Three hours after vehicle or drug administration, mice were anesthetized with a mixture of ketamine/xylazine (200/5 mg/kg s.c.). Muscle tissue was dissected away from the cisterna magna, the skull around the cisterna magna was cleaned to remove traces of blood, and CSF was collected via a fine-tipped pipette. Samples were frozen immediately on dry ice. Blood samples were obtained by cardiac puncture, collected in EDTA-coated tubes, and centrifuged (2400 rpm; 20 min) within1hof collection to separate the plasma. In the first study of s.c. DAPT administration, whole brains were removed and frozen immediately over liquid nitrogen. The dorsal hippocampus and prefrontal cortex were later dissected from 1-mm-thick coronal sections using a surgical knife. In all subsequent studies, the entire hippocampus (bilateral) and overlying cerebral cortex from one hemisphere were removed immediately after excising the brains from the skulls and frozen on dry ice. The brain samples were homogenized in 5 M guanidine buffer (5M guanidine HCl in 50 mM Tris-Cl, pH 8.0) at 1:10 dilution. Homogenates were agitated at room temperature for 3 to 4 h and then stored at —20°C. The day before running the ELISA, the 1:10 samples in 5 M guanidine were diluted further 1:10 for a final guanidine concentration of 0.5 M. The homogenates were then spun down at 14,000 rpm for 20 min at 4°C, and supernatants were used for A determination by ELISA.

A ELISA. CSF and plasma samples were thawed and diluted in blocking buffer (phosphate-buffered saline, 0.05% Tween 20, 1% bovine serum albumin); CSF volumes of 2 to 12 µl were diluted up to 125 µl, and plasma was diluted 1:2. Brain extracts from the young mice were diluted 1:100. Due to very high A levels in the brains of old animals, cortical samples were diluted 1:20,000 for A(1-40) and 1:12,000 for A(1-42); hippocampal samples were diluted 1:10,000 for A(1-40) and 1:8,000 for A(1-42).

Half-volume, 96-well plates were coated overnight at 4°C with capture antibody 6E10 (Signet Laboratories, Dedham, MA) diluted 1:250 in 0.1 M NaHCO₃, pH 8.2. Standard curves were prepared in blocking buffer (or guanidine buffer for brain homogenates) from stock solutions of A(1-40) and A(1-42). Standards and samples were incubated for 3 h at room temperature. For detection, biotinylated rabbit polyclonal antibodies directed against A(1-40) (Rb 209) and A(1-42) (Rb 321) were used. After signal amplification with horseradish peroxidase-conjugated neutravidin, protein levels were visualized using a 3,3',5,5'-tetramethylbenzidine peroxidase substrate kit (Kirkegaard and Perry Laboratories, Gaithersburg, MD); color development was stopped after 1 h with 1 M H₃PO4. Plates were read at 450 nm on a microplate reader, and 4-par logistics were used to extrapolate unknown values from the standard curves.

Measurement of DAPT Levels in Brain Tissue and Plasma. Analysis of DAPT concentration in brain tissue and plasma was performed by liquid chromatography mass spectroscopy after organic solvent extraction from brain homogenates and plasma. One hemisphere of frozen brain tissue was weighed and homogenized in 0.9% saline (1:1 by weight). Similarly, plasma samples were mixed with an equal volume of mobile phase buffer (20 mM ammonium acetate, pH 4.5). An equal volume of 25 µM flurbiprofen (internal standard) was added to each sample, and proteins were precipitated in acetonitrile. The samples were centrifuged and the resulting supernatants were used for DAPT measurement. For quantification, standard curves were constructed using brain homogenates or plasma from vehicle-treated animals containing DAPT and internal standard. Samples were injected onto the liquid chromatography mass spectroscopy and quantified by multireaction monitoring. The analysis was performed with a PE-Sciex, API 4000 triple-quadrapole mass spectrometer (Applied Biosystems, Toronto, ON, Canada) with a Turbo Ionspray source, equipped with a PerkinElmer series 200 micropump and series 200 autosampler (PerkinElmer Instruments, Norwalk, CT). Separation was performed with a Zorbax SB-CN (2.1 x 150 mm, 5 µm) column using acetonitrile and 20 mM ammonium acetate, pH 4.5, as mobile phases. Data acquisition and analysis were carried out with PE-Sciex Analyst software (version 1.2).

Statistical Analysis. For each age group, one-way analysis of variance was used to detect a significant treatment effect for A(1-40) and A(1-42) in the separate tissue compartments. After a significant treatment effect, individual dose differences were analyzed with a Fisher's protected least significant difference test; p < 0.05 was set as a statistically significant level for both tests.

	Results

Top Abstract Materials and Methods Results Discussion References

 
Effects of DAPT (10, 30, and 100 mg/kg s.c.) on Brain and Plasma A Levels in Young Tg2576 Mice. As reported by Dovey et al. (2001), acute DAPT administration dose dependently reduced A(1-40) (F_3,12 = 3.068, p < 0.05), and to some degree A(1-42) (F_3,12 = 2.215, p < 0.10) in the cortex. The highest dose, 100 mg/kg s.c., was the only effective dose (p < 0.05) with respect to both A(1-40) and A(1-42), eliciting a 38 to 40% reduction compared with the respective vehicle-treated group (Fig. 1, A and B). No treatment effect was detected in the hippocampus for either A(1-40) (F_3,12 = 2.146, p = 0.11) or A(1-42) (F_3,12 = 2.248, p = 0.10).

View larger version (46K): [in this window] [in a new window]   Fig. 1. A and B, effects of acute s.c. DAPT administration on A levels in the cortex and hippocampus in young Tg2576 mice. Filled columns represent mean A concentration ± S.E.M. for cortex; open columns represent mean A concentration ± S.E.M. for hippocampus. C and D, mean A concentration ± S.E.M. in plasma (*, p < 0.05; **, p < 0.001).

Consistent with greater levels of DAPT in the plasma than in the brain (Table 1), DAPT produced greater reductions in A levels in the plasma than in the brain. Thus, a significant treatment effect was evident for both A(1-40) (F_3,12 = 13.502, p < 0.001) and A(1-42) (F_3,12 = 8.329, p < 0.001). The 100 mg/kg s.c. dose significantly reduced A(1-40) (53% reduction, p < 0.001) and A(1-42) (51% reduction, p < 0.001) compared with vehicle-treated mice (Fig. 1, C and D). Additionally, the 30 mg/kg s.c. dose effectively reduced A(1-40) (35% reduction, p < 0.001) and A(1-42) (27% reduction, p < 0.05); the 10-mg/kg dose had no significant effect.

Effects of DAPT (10, 30, and 100 mg/kg s.c.) on Brain, CSF, and Plasma A Levels in Aged Tg2576 Mice. Plasma and brain DAPT levels in aged mice were comparable with those in young animals described above (Table 1). Acute DAPT had no effect on either cortical or hippocampal A concentrations in the aged Tg2576 mice (Fig. 2, A and B). This is not surprising, given the fact that the brain extracts of older mice contained about 500 times as much A as that seen in young mice, most of which likely represents A extracted from amyloid plaque deposits.

View larger version (42K): [in this window] [in a new window]   Fig. 2. Effects of acute s.c. DAPT administration on A levels in the brains (A and B), CSF (C and D), and plasma (E and F) of old Tg2576 mice. Filled columns (A and B) represent cortical A; open columns represent hippocampal A (mean concentration ± S.E.M.; *, p < 0.05; **, p < 0.01, ***, p < 0.001).

In the CSF (Fig. 2, C and D), however, where A concentrations resemble those of younger mice, DAPT significantly reduced A(1-40) (F_3,12 = 4.246, p < 0.01) and A(1-42) (F_3,12 = 3.58, p < 0.01). Treatment with 100 mg/kg s.c. DAPT produced a significant decrease in both A(1-40) (42% reduction, p < 0.05) and A(1-42) (49% reduction, p < 0.01). The 30 mg/kg s.c. dose produced a significant decrease (30%) in only A(1-42) (p < 0.05).

In the plasma (Fig. 2, E and F), there was a strong treatment effect on both A(1-40) (F_3,12 = 21.104, p < 0.001) and A(1-42) (F_3,12 = 6.832, p < 0.001) as seen in the young mice. DAPT-treated mice had reduced A(1-40) levels at both the 30-mg/kg (40% reduction, p < 0.001) and 100-mg/kg doses (65% decrease, p < 0.001). A(1-42) was reduced in old mice by the 100-mg/kg dose only (55% reduction, p < 0.001).

Effects of DAPT (100 and 200 mg/kg p.o.) on A Levels in the Brain, CSF, and Plasma in Young and Aged Tg2576 Mice. Oral DAPT produced somewhat more variable exposures in both the brain and plasma than those seen after s.c. administration (Table 1). However, the levels at 3 h after oral DAPT administration were comparable between young and aged mice as seen in the previous studies after s.c. administration. Additionally, DAPT concentrations in the plasma and brain did not differ between animals treated with 100- and 200-mg/kg doses.

Acute oral administration of DAPT produced a significant reduction of cortical A(1-40) (F_2,13 = 31.575, p < 0.001) and A(1-42) (F_2,13 = 5.293, p < 0.01), as well as hippocampal A(1-40) (F_2,13 = 37.475, p < 0.001) and A(1-42) (F_2,13 = 10.003, p < 0.001) in young mice (Fig. 3, A and B). Both 100 and 200 mg/kg DAPT significantly reduced A(1-40) and A(1-42) in cortex (p < 0.01) and hippocampus (p < 0.001) compared with the vehicle. DAPT (100 mg/kg p.o.) reduced A(1-40) by 46 and 50% in the cortex and hippocampus, respectively. These reductions rose to 57% in the cortex and 56% in the hippocampus with the 200-mg/kg p.o. dose, but were not significantly different from the reductions seen after 100 mg/kg. In older animals, such a robust effect of DAPT on brain A levels was not seen (Fig. 3, C and D), although a significant treatment effect was detected in only the cortex for A(1-40) (F_2,13 = 4.012, p < 0.05), but not A(1-42) (F_2,13 = 1.513, p = 0.23). The former was significantly reduced by the 100-mg/kg (23% reduction, p < 0.05) and 200-mg/kg (28% reduction, p < 0.05) dose. This treatment effect in the brains of old Tg2576 mice was not replicated, however, in a separate group of 16-month-old Tg2576 mice given either the vehicle or DAPT (100 mg/kg) orally. After vehicle, A(1-40) was 45,754 ± 4,750 nM in the cortex and 28,090 ± 3,400 in the hippocampus. DAPT treatment resulted in A(1-40) level of 40,959 ± 2,339 nM in the cortex (F_1,14 = 1.064, p = 0.31) and 24,889 ± 1,264 nM A(1-40) in the hippocampus (F_1,14 = 0.693, p = 0.41). Levels of A(1-42) were 3,512 ± 232 nM in cortex and 2,467 ± 189 in hippocampus after vehicle treatment, and 3,359 ± 169 nM in cortex (F_1,14 = 0.282, p = 0.6) and 2,214 ± 140 in hippocampus after DAPT (F_1,14 = 1.153, p = 0.29).

View larger version (31K): [in this window] [in a new window]   Fig. 3. Effects of acute p.o. DAPT administration on A levels in the cortex and hippocampus in young (A and B) and old (C and D) Tg2576 mice. Filled columns represent mean A concentration ± S.E.M. for cortex; open columns represent mean A concentration ± S.E.M. for hippocampus.

Unlike the brain tissue, CSF did not show a significant difference in either A(1-40) or A(1-42) between young and old vehicle-treated mice. Acute, oral DAPT exerted a strong treatment effect on CSF A(1-40) (F_2,13 = 13.536, p < 0.001) and A(1-42) (F_2,13 = 6.018, p < 0.001) in both young and old mice. Consistent with similar exposures in the brain, both doses produced equivalent decreases in CSF A peptide levels. CSF A(1-40) was reduced by 72 to 74% in young mice (p < 0.001) and 53 to 58% in old mice (p < 0.001; Fig. 4A). A(1-42) decreased by 46 to 58% in the young mice (p < 0.01) and 51 to 62% in the old mice (p < 0.001; Fig. 4B). There were no significant differences between the magnitude of DAPT-induced A reduction in the CSF between the young and aged mice.

View larger version (28K): [in this window] [in a new window]   Fig. 4. Effects of acute p.o. DAPT administration on CSF (A and B) and plasma (C and D) A. Filled columns represent young mice; open columns represent old mice (*, p < 0.05; **, p < 0.01; ***, p < 0.001).

As seen with s.c. doses of DAPT, the treatment effect in plasma was very robust for A(1-40) (F_2,13 = 19.710, p < 0.001) and A(1-42) (F_2,13 = 4.014, p < 0.001) in both young and old Tg2576 mice. The two doses tested did not differ from each other with respect to the magnitude of A reductions, as expected on the basis of evidence of similar plasma concentrations (Table 1). Plasma A(1-40) was reduced by 60 to 74% in young mice (p < 0.001), and by 51 to 53% in aged mice (p < 0.001; Fig. 4C). Plasma A(1-42) decreased 35 to 39% in young mice (p < 0.001) and up to 30% in the old mice (p < 0.05; Fig. 4D). Levels of A(1-40) and A(1-42) did not significantly differ between young and old mice in vehicle-treated animals.

	Discussion

Top Abstract Materials and Methods Results Discussion References

 
The present study replicates and extends the findings of Dovey et al. (2001) by demonstrating that acute treatment with the -secretase inhibitor, DAPT, dose dependently reduces cortical A levels in young Tg2576 mice expressing human APP with Swedish familial mutation (hAPP_Sw). The magnitude (38–40%) of reduction in brain A(1-40) and A(1-42) levels in young mice treated with DAPT (100 mg/kg s.c.) was consistent with the 40 to 50% reduction in total A(1-x) levels reported by Dovey et al. (2001). In addition, the data provide evidence that DAPT dose dependently reduces A peptide levels in both the CSF and the plasma of aged, plaque-bearing Tg2576 mice. The magnitude of A reduction in the CSF and plasma of aged mice was comparable with that seen in the respective fluids from young Tg2576 mice. These results suggest that A reduction provides a mechanism-based measure of -secretase inhibition, regardless of the presence of amyloid plaques. Hence, the data reported here provide support to a recently published mathematical model (Craft et al., 2002) of A accumulation in AD that predicts that agents (such as -or -secretase inhibitors) that inhibit the production of A are likely to cause reductions in A concentrations in the three major interrelated compartments: the brain, CSF, and plasma.

The absolute levels of hippocampal and cortical A(1-40) and A(1-42) differed between the two studies (s.c. versus p.o. administration) described here. We believe this may be due to the differential tissue dissecting techniques applied in the two studies. In the first study when DAPT was administered via the s.c. route, A peptide levels were assessed in dorsal hippocampus and prefrontal cortex excised out of frozen brains from both young and aged mice. In contrast, the subsequent studies of oral DAPT administration used the entire cerebral cortex removed from one hemisphere and bilaterally dissected hippocampal formation from freshly removed brains. The assessment of only dorsal hippocampal A concentration could be the reason also why hippocampal A decreases were not evident in the young mice in the study assessing s.c. DAPT effects. It should be noted that the absolute levels of A(1-40) and A(1-42) when assessed from the whole cortex and hippocampus are in pretty good agreement with those reported by Kawarabayashi et al. (2001) for the Tg2576 mice.

In contrast to the CSF and plasma, DAPT reduced A levels in the brain primarily in the young Tg2576 mice. Although a small decrease in brain A(1-40) level was detected in aged mice after one of the oral DAPT studies (Fig. 3), this effect was not seen after either s.c. DAPT treatment or a subsequent oral DAPT efficacy study. The differential reduction in A levels in young versus aged mice is likely attributed to different sources of A in brain extracts from the two age groups. Thus, A measured in brain extracts from young mice largely reflects undeposited, newly processed APP metabolism products, whereas in the aged mice, amyloid deposits are the major source of the A peptides. This is supported by the data that brain A concentrations in vehicle-treated, 17-month-old mice were about 500 times greater than those in young control mice. On the other hand, vehicle-treated mice showed no age-related differences in CSF or plasma A concentrations. A recent report by Kawarabayashi et al. (2001) demonstrated age-dependent reduction in CSF and plasma A levels in Tg2576 mice; however, a significant difference was not seen before 18 to 23 months of age in these mice. Hence, the inability to detect a significant age-related reduction in plasma or CSF A levels in the present study may be due the somewhat younger age (16–17 months) of the mice used in our study.

The relationship between brain, CSF, and plasma A pools with progression of the disease in AD patients remains to be fully elucidated. As discussed previously, several, although not all, studies demonstrate that AD patients have higher plasma and lower CSF A peptide levels than age-matched controls (Motter et al., 1995; Nitsch et al., 1995; Matsubara et al., 1999; Mehta et al., 2001). These studies have led to the suggestion that sequestration of A peptides by amyloid plaques may alter the kinetics of A and thereby modulate also A pharmacodynamics in response to therapeutic agents aimed at reducing brain A levels. The data shown here clearly demonstrate that the ability of the -secretase inhibitor, DAPT, to reduce CSF and plasma A levels is independent of brain plaque burden. Thus, in clinical trials of AD where all patients are likely to have a significant amyloid plaque burden, CSF A may offer a viable biomarker of - and -secretase inhibitors that block processing of APP to A. Additionally, our data indicate that the decreases in CSF and plasma A levels in older transgenic mice (Kawarabayashi et al., 2001), and some clinical samples from Alzheimer's patients may not result simply due to A deposition into plaques; other factors such as neuronal degeneration or dysfunction may be involved.

Whether CSF and plasma A reduction in the Tg2576 mice reflects inhibition of APP processing in the brain or the peripheral tissue is not entirely clear from the data shown here. In the Tg2576 mice, it is likely that A is being generated in the periphery because the transgene (hAPP_Sw) expression can be detected in several peripheral organs (Kawarabayashi et al., 2001). Hence, peripheral -secretase inhibition may contribute to the observed plasma A decreases. On the other hand, central injections of A in mice and rats have been shown to diffuse fairly quickly into the blood and parenchymal vasculature (Ghersi-Egea et al., 1996; Shibata et al., 2000). These data suggest that central -secretase inhibition also may be reflected in plasma A decreases after DAPT treatment. Thus, the utility of plasma A decrease as a marker of central inhibition of APP processing needs to be further established. In contrast, it is likely that CSF A reduction may primarily reflect inhibition of cleavage of APP in the brain. Although an active transport of A from the plasma to the brain has been demonstrated (Zlokovic et al., 1993; Martel et al., 1996), the net contribution of the plasma A pool to the total CSF A pool may be relatively small because plasma A levels are about 1/50th of those found in the brain. However, in view of the active transport mechanism for A across the blood-brain barrier, definitive studies will be needed to clarify the role of peripheral -secretase inhibition on kinetics of central A compartments. Recent studies of A sequestering agents such as a high-affinity anti-A antibody (DeMattos et al., 2001, 2002), gelsolin, and ganglioside GM1 (Matsuoka et al., 2003) suggest that sustained sequestration of peripheral A reduces central A levels. These studies suggest that there may be dynamic interactions between the central and peripheral pools of A. It remains to be seen whether compounds that reduce plasma A levels by inhibiting its production can also affect central A levels. It would be interesting to test the effects of a nonbrain-penetrant - or -secretase inhibitor to understand further the dynamics of A pools in the plasma and central compartments.

Because CSF is in direct contact with the extracellular fluid in the brain, it is likely that CSF A levels reflect A in extracellular brain levels. The fact that DAPT reduces brain and CSF A levels in the young, nonplaque-bearing mice but only CSF A levels in the aged mice has led us to hypothesize that CSF A levels are indicative of a nondeposited form of A that can be modulated by -secretase. Future studies using differential extraction procedures to assess soluble versus nonsoluble pools of brain A and their correlation with CSF A will help characterize further the A pools affected by after - or -secretase inhibition.

In summary, the current study demonstrates the efficacy of an acute dose of a -secretase inhibitor in reducing A(1-40) and A(1-42) in vivo in both central and peripheral compartments of Tg2576 mice. To our knowledge, this is the first report examining the relationship between A in brain, CSF, and plasma compartments in the presence or absence of brain amyloid plaques after inhibition of APP processing by a -secretase inhibitor. The data presented here suggest that CSF A levels may be used as a biochemical biomarker to establish proof of mechanism in clinical studies of - or -secretase inhibitors in Alzheimer's disease patients. However, studies of secretase inhibition on endogenous APP processing using nontransgenic animals are required to confirm the utility of plasma and CSF A levels as a biomarker for clinical studies of sporadic Alzheimer's Disease patients. Of course, the clinical utility of - or -secretase inhibitors as disease-modifying therapies for Alzheimer's disease will have to take into account the potential liability resulting from inhibition of processing of other substrates of these enzymes.

	Acknowledgements

 
We thank Phillip Sanders and Peter Ellefson for mass spectrometry technical support, and Lisa Toth for assistance with drug concentration analysis.

	Footnotes

 
Article, publication date, and citation information can be found at http://jpet.aspetjournals.org.

DOI: 10.1124/jpet.102.048280.

ABBREVIATIONS: AD, Alzheimer's disease; A, amyloid-; APP, amyloid-precursor protein; DAPT, N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester; CSF, cerebrospinal fluid; ELISA, enzyme-linked immunosorbent assay.

Address correspondence to: Dr. Kalpana M. Merchant, Pharmacia Corporation, 301 Henrietta St., Mailstop 7251-209-506, Kalamazoo, MI 49007. E-mail: kalpana.m.merchant{at}pharmacia.com

	References

Top Abstract Materials and Methods Results Discussion References

 

Andreasen N and Blennow K (2002) -Amyloid (A) protein in cerebrospinal fluid as a biomarker for Alzheimer's disease. Peptides 23: 1205–1214.[CrossRef][Medline]

Andreasen N, Hesse C, Davidsson P, Wallin A, Minthon L, Winblad B, Vanderstichele H, Vanmechelen E, and Blennow K (1999) Cerebrospinal fluid -amyloid_(1-42) in Alzheimer's disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. Arch Neurol 56: 673–680.[Abstract/Free Full Text]

Chapman PF, Falinska AM, Knevett SG, and Ramsay MF (2001) Genes, models and Alzheimer's disease. Trends Genet 17: 254–261.[CrossRef][Medline]

Citron M, Oltersdorf T, Haass C, McConlogue L, Hung AY, Seubert P, Vigo-Pelfrey C, Lieberburg I, and Selkoe DJ (1992) Mutation of the -amyloid precursor protein in familial Alzheimer's disease increases beta-protein production. Nature (Lond) 360: 672–674.[CrossRef][Medline]

Craft DL, Wein LM, and Selkoe DJ (2002) A mathematical model of the impact of novel treatments on the A burden in the Alzheimer's brain, CSF and plasma. Bull Math Biol 64: 1011–1031.[CrossRef][Medline]

DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, and Holtzman DM (2001) Peripheral anti-A antibody alters CNS and plasma A clearance and decreases brain A burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 98: 8850–8855.[Abstract/Free Full Text]

DeMattos RB, Bales KR, Cummins DJ, Paul SM, and Holtzman DM (2002) Brain to plasma amyloid- efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science (Wash DC) 295: 2264–2267.[Abstract/Free Full Text]

Dovey HF, John V, Anderson JP, Chen LZ, de Saint Andrieu P, Fang LY, Freedman SB, Folmer B, Goldbach E, Holsztynska EJ, et al. (2001) Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain. J Neurochem 76: 173–181.[CrossRef][Medline]

Ghersi-Egea JF, Gorevic PD, Ghiso J, Frangione B, Patlak CS, and Fenstermacher JD (1996) Fate of cerebrospinal fluid-borne amyloid -peptide: rapid clearance into blood and appreciable accumulation by cerebral arteries. J Neurochem 67: 880–883.[Medline]

Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, and Cole G (1996) Correlative memory deficits, A elevation and amyloid plaques in transgenic mice. Science (Wash DC) 274: 99–102.[Abstract/Free Full Text]

Ida N, Hartmann T, Pantel J, Schroder J, Zerfass R, Forstl H, Sandbrink R, Masters CL, and Beyreuther K (1996) Analysis of heterogeneous A4 peptides in human cerebrospinal fluid and blood by a newly developed sensitive Western blot assay. J Biol Chem 271: 22908–22914.[Abstract/Free Full Text]

Janus C and Westaway D (2001) Transgenic mouse models of Alzheimer's disease. Physiol Behav 73: 873–886.[CrossRef][Medline]

Kawarabayashi T, Younkin LH, Saido TC, Shoji M, Ashe KH, and Younkin SG (2001) Age-dependent changes in brain, CSF and plasma amyloid () protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J Neurosci 21: 372–381.[Abstract/Free Full Text]

Martel CL, Mackic JB, McComb JG, Ghiso J, and Zlokovic BV (1996) Blood–brain barrier uptake of the 40 and 42 amino acid sequences of circulating Alzheimer's amyloid in guinea pigs. Neurosci Lett 206: 157–160.[CrossRef][Medline]

Matsubara E, Ghiso J, Frangione B, Amari M, Tomidokoro Y, Ikeda Y, Harigaya Y, Okamoto K, and Shoji M (1999) Lipoprotein-free amyloidogenic peptides in plasma are elevated in patients with sporadic Alzheimer's disease and Down's syndrome. Ann Neurol 45: 537–541.[CrossRef][Medline]

Matsuoka Y, Saito M, LaFrancois J, Saito M, Gaynor K, Olm V, Wang L, Casey E, Lu Y, Shiratori C, Lemere C, and Duff K (2003) Novel therapeutic approach for the treatment of Alzheimer's disease by peripheral administration of agents with an affinity to -amyloid. J Neurosci 23: 29–33.[Abstract/Free Full Text]

May PC, Alstiel L, Bender MH, Boggs LN, Calligaro DO, Fuson KS, Gitter BD, Hyslop PA, Jordan WH, Li WY, et al. (2001) Marked Reduction of A accumulation and -amyloid plaque pathology in mice upon chronic treatment with a functional -secretase inhibitor. Soc Neurosci Abstr 27: 687.1.

Mayeux R, Tang MX, Jacobs DM, Manly J, Bell K, Merchant C, Small SA, Stern Y, Wisniewski HM, and Mehta PD (1999) Plasma amyloid beta-peptide 1-42 and incipient Alzheimer's disease. Ann Neurol 46: 412–416.[CrossRef][Medline]

Mehta PD, Pirttila T, Mehta SP, Sersen EA, Aisen PS, and Wisniewski HM (2000) Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease. Arch Neurol 57: 100–105.[Abstract/Free Full Text]

Mehta PD, Pirttila T, Patrick BA, Barshatzky M, and Mehta SP (2001) Amyloid beta protein 1-40 and 1-42 levels in matched cerebrospinal fluid and plasma from patients with Alzheimer disease. Neurosci Lett 304: 102–106.[CrossRef][Medline]

Motter R, Vigo-Pelfrey C, Kholodenko D, Barbour R, Johnson-Wood K, Galasko D, Chang L, Miller B, Clark C, Green R, et al. (1995) Reduction of b-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol 38: 643–648.[CrossRef][Medline]

Nitsch RM, Rebeck GW, Deng M, Richardson UI, Tennis M, Schenk DB, Vigo-Pelfrey C, Lieberburg I, Wurtman RJ, Hyman BT, and Growdon JH (1995) Cerebrospinal fluid levels of amyloid -protein in Alzheimer's disease: inverse correlation with severity of dementia and effect of A apolipoprotein E genotype. Ann Neurol 37: 512–518.[CrossRef][Medline]

Rishton GM, Retz DM, Tempest PA, Novotny J, Kahn S, Treanor JJ, Lile JD, and Citron M (2000) Fenchylamine sulfonamide inhibitors of amyloid peptide production by the -secretase proteolytic pathway: potential small-molecule therapeutic agents for the treatment of Alzheimer's disease. J Med Chem 43: 2297–2299.[CrossRef][Medline]

Scheuner D, Eckman C, Jensen M, Song X, Citron M, Suzuki N, Bird TD, Hardy J, Hutton M, Kukull W, et al. (1996) Secreted amyloid -protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat Med 2: 864–870.[CrossRef][Medline]

Seubert P, Vigo-Pelfrey C, Esch F, Lee M, Dovey H, Davis D, Sinha S, Schlossmacher M, Whaley J, and Swindlehurst C (1992) Isolation and quantification of soluble Alzheimer's -peptide from biological fluids. Nature (Lond) 359: 325–327.[CrossRef][Medline]

Shearman MS, Beher D, Clarke EE, Lewis HD, Harrison T, Hunt P, Nadin A, Smith AL, Stevenson G, and Castro JL (2000) L-685,458, an aspartyl protease transition state mimic, is a potent inhibitor of amyloid -protein precursor -secretase activity. Biochemistry 39: 8698–86704.[CrossRef][Medline]

Shibata M, Yamada S, Kumar SR, Calero M, Bading J, Frangione B, Holtzman DM, Miller CA, Strickland DK, Ghiso J, et al. (2000) Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J Clin Investig 106: 1489–1499.[Medline]

Steinhilb ML, Turner RS, and Gaut JR (2001) The protease inhibitor, MG132, blocks maturation of the amyloid precursor protein Swedish mutant preventing cleavage by -secretase. J Biol Chem 276: 4476–4484.[Abstract/Free Full Text]

Suzuki N, Cheung TT, Cai XD, Odaka A, Otvos L Jr, Eckman C, Golde TE, and Younkin SG (1994) An increased percentage of long amyloid protein secreted by familial amyloid protein precursor ( APP717) mutants. Science (Wash DC) 264: 1336–1340.[Abstract/Free Full Text]

Tamaoka A, Fukushima T, Sawamura N, Ishikawa K, Oguni E, Komatsuzaki Y, and Shoji S (1996) Amyloid protein in plasma from patients with sporadic Alzheimer's disease. J Neurol Sci 141: 65–68.[CrossRef][Medline]

Tanzi RE, Kovacs DM, Kim TW, Moir RD, Guenette SY, and Wasco W (1996) The gene defects responsible for familial Alzheimer's disease. Neurobiol Dis 3: 159–168.[CrossRef][Medline]

Zlokovic BV, Ghiso J, Mackic JB, McComb JG, Weiss MH, and Frangione B (1993) Blood-brain barrier transport of circulating Alzheimer's amyloid. Biochem Biophys Res Commun 197: 1034–1040.[CrossRef][Medline]

This article has been cited by other articles:

				J. L. Cummings, R. Doody, and C. Clark Disease-modifying therapies for Alzheimer disease: Challenges to early intervention Neurology, October 16, 2007; 69(16): 1622 - 1634. [Abstract] [Full Text] [PDF]

				M. E. Goldstein, Y. Cao, T. Fiedler, J. Toyn, L. Iben, D. M. Barten, M. Pierdomenico, J. Corsa, C. V. C. Prasad, R. E. Olson, et al. Ex Vivo Occupancy of {gamma}-Secretase Inhibitors Correlates with Brain beta-Amyloid Peptide Reduction in Tg2576 Mice J. Pharmacol. Exp. Ther., October 1, 2007; 323(1): 102 - 108. [Abstract] [Full Text] [PDF]

				J. H. Park, G. A. Widi, D. A. Gimbel, N. Y. Harel, D. H. S. Lee, and S. M. Strittmatter Subcutaneous Nogo Receptor Removes Brain Amyloid-{beta} and Improves Spatial Memory in Alzheimer's Transgenic Mice J. Neurosci., December 20, 2006; 26(51): 13279 - 13286. [Abstract] [Full Text] [PDF]

				L. A. Hyde, N. A. McHugh, J. Chen, Q. Zhang, D. Manfra, A. A. Nomeir, H. Josien, T. Bara, J. W. Clader, L. Zhang, et al. Studies to Investigate the in Vivo Therapeutic Window of the {gamma}-Secretase Inhibitor N2-[(2S)-2-(3,5-Difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide (LY411,575) in the CRND8 Mouse J. Pharmacol. Exp. Ther., December 1, 2006; 319(3): 1133 - 1143. [Abstract] [Full Text] [PDF]

				T. A. Lanz, M. J. Karmilowicz, K. M. Wood, N. Pozdnyakov, P. Du, M. A. Piotrowski, T. M. Brown, C. E. Nolan, K. E. G. Richter, J. E. Finley, et al. Concentration-Dependent Modulation of Amyloid-beta in Vivo and in Vitro Using the {gamma}-Secretase Inhibitor, LY-450139 J. Pharmacol. Exp. Ther., November 1, 2006; 319(2): 924 - 933. [Abstract] [Full Text] [PDF]

				J. D. Best, M. T. Jay, F. Otu, I. Churcher, M. Reilly, P. Morentin-Gutierrez, C. Pattison, T. Harrison, M. S. Shearman, and J. R. Atack In Vivo Characterization of Abeta(40) Changes in Brain and Cerebrospinal Fluid Using the Novel {gamma}-Secretase Inhibitor N-[cis-4-[(4-Chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexyl]-1,1,1-trifluoromethanesulfonamide (MRK-560) in the Rat J. Pharmacol. Exp. Ther., May 1, 2006; 317(2): 786 - 790. [Abstract] [Full Text] [PDF]

				L. Desire, J. Bourdin, N. Loiseau, H. Peillon, V. Picard, C. De Oliveira, F. Bachelot, B. Leblond, T. Taverne, E. Beausoleil, et al. RAC1 Inhibition Targets Amyloid Precursor Protein Processing by {gamma}-Secretase and Decreases A{beta} Production in Vitro and in Vivo J. Biol. Chem., November 11, 2005; 280(45): 37516 - 37525. [Abstract] [Full Text] [PDF]

				J. D. Best, M. T. Jay, F. Otu, J. Ma, A. Nadin, S. Ellis, H. D. Lewis, C. Pattison, M. Reilly, T. Harrison, et al. Quantitative Measurement of Changes in Amyloid-{beta}(40) in the Rat Brain and Cerebrospinal Fluid following Treatment with the {gamma}-Secretase Inhibitor LY-411575 [N2-[(2S)-2-(3,5-Difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide] J. Pharmacol. Exp. Ther., May 1, 2005; 313(2): 902 - 908. [Abstract] [Full Text] [PDF]

				D. M. Barten, V. L. Guss, J. A. Corsa, A. Loo, S. B. Hansel, M. Zheng, B. Munoz, K. Srinivasan, B. Wang, B. J. Robertson, et al. Dynamics of {beta}-Amyloid Reductions in Brain, Cerebrospinal Fluid, and Plasma of {beta}-Amyloid Precursor Protein Transgenic Mice Treated with a {gamma}-Secretase Inhibitor J. Pharmacol. Exp. Ther., February 1, 2005; 312(2): 635 - 643. [Abstract] [Full Text] [PDF]

				T. A. Lanz, G. J. Fici, and K. M. Merchant Lack of Specific Amyloid-{beta}(1-42) Suppression by Nonsteroidal Anti-Inflammatory Drugs in Young, Plaque-Free Tg2576 Mice and in Guinea Pig Neuronal Cultures J. Pharmacol. Exp. Ther., January 1, 2005; 312(1): 399 - 406. [Abstract] [Full Text] [PDF]

				U. Keil, A. Bonert, C. A. Marques, I. Scherping, J. Weyermann, J. B. Strosznajder, F. Muller-Spahn, C. Haass, C. Czech, L. Pradier, et al. Amyloid {beta}-induced Changes in Nitric Oxide Production and Mitochondrial Activity Lead to Apoptosis J. Biol. Chem., November 26, 2004; 279(48): 50310 - 50320. [Abstract] [Full Text] [PDF]

				A. C. Nyborg, K. Jansen, T. B. Ladd, A. Fauq, and T. E. Golde A Signal Peptide Peptidase (SPP) Reporter Activity Assay Based on the Cleavage of Type II Membrane Protein Substrates Provides Further Evidence for an Inverted Orientation of the SPP Active Site Relative to Presenilin J. Biol. Chem., October 8, 2004; 279(41): 43148 - 43156. [Abstract] [Full Text] [PDF]

				M. Sadowski, J. Pankiewicz, H. Scholtzova, J. A. Ripellino, Y. Li, S. D. Schmidt, P. M. Mathews, J. D. Fryer, D. M. Holtzman, E. M. Sigurdsson, et al. A Synthetic Peptide Blocking the Apolipoprotein E/{beta}-Amyloid Binding Mitigates {beta}-Amyloid Toxicity and Fibril Formation in Vitro and Reduces {beta}-Amyloid Plaques in Transgenic Mice Am. J. Pathol., September 1, 2004; 165(3): 937 - 948. [Abstract] [Full Text] [PDF]

				K. Gowrishankar, M. G. Zeidler, and C. Vincenz Release of a membrane-bound death domain by {gamma}-secretase processing of the p75NTR homolog NRADD J. Cell Sci., August 15, 2004; 117(18): 4099 - 4111. [Abstract] [Full Text] [PDF]

				T. A. Lanz, J. D. Hosley, W. J. Adams, and K. M. Merchant Studies of A{beta} Pharmacodynamics in the Brain, Cerebrospinal Fluid, and Plasma in Young (Plaque-Free) Tg2576 Mice Using the {gamma}-Secretase Inhibitor N2-[(2S)-2-(3,5-Difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide (LY-411575) J. Pharmacol. Exp. Ther., April 1, 2004; 309(1): 49 - 55. [Abstract] [Full Text]

				G. T. Wong, D. Manfra, F. M. Poulet, Q. Zhang, H. Josien, T. Bara, L. Engstrom, M. Pinzon-Ortiz, J. S. Fine, H.-J. J. Lee, et al. Chronic Treatment with the {gamma}-Secretase Inhibitor LY-411,575 Inhibits {beta}-Amyloid Peptide Production and Alters Lymphopoiesis and Intestinal Cell Differentiation J. Biol. Chem., March 26, 2004; 279(13): 12876 - 12882. [Abstract] [Full Text] [PDF]

				S. Weggen, J. L. Eriksen, S. A. Sagi, C. U. Pietrzik, V. Ozols, A. Fauq, Todd. E. Golde, and E. H. Koo Evidence That Nonsteroidal Anti-inflammatory Drugs Decrease Amyloid {beta}42 Production by Direct Modulation of {gamma}-Secretase Activity J. Biol. Chem., August 22, 2003; 278(34): 31831 - 31837. [Abstract] [Full Text] [PDF]

				S. Weggen, J. L. Eriksen, S. A. Sagi, C. U. Pietrzik, Todd. E. Golde, and E. H. Koo A{beta}42-lowering Nonsteroidal Anti-inflammatory Drugs Preserve Intramembrane Cleavage of the Amyloid Precursor Protein (APP) and ErbB-4 Receptor and Signaling through the APP Intracellular Domain J. Biol. Chem., August 15, 2003; 278(33): 30748 - 30754. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) All Versions of this Article: jpet.102.048280v1 305/3/864    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lanz, T. A. Articles by Merchant, K. M. Search for Related Content PubMed PubMed Citation Articles by Lanz, T. A. Articles by Merchant, K. M.